ArticleJournal of psychopharmacology (Oxford, England)2017
Effects of varenicline on alcohol self-administration and craving in drinkers with depressive symptoms.
Article in Journal of psychopharmacology (Oxford, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- Efficacy of Varenicline in the Treatment of Alcohol Dependence: An Updated Meta-Analysis and Meta-Regression.International journal of environmental research and public health · 2023Pooled it
- Alcohol use disorder severity moderates clinical response to varenicline.Alcoholism, clinical and experimental research · 2021Trial
- Cholinergic regulation of prolonged alcohol withdrawal differs by sex.bioRxiv : the preprint server for biology · 2025Article
- α4 Nicotinic Acetylcholine Receptors in Lipopolysaccharide-Related Lung Inflammation.International journal of molecular sciences · 2024Article
- Antismoking agents do not contribute synergistically to semaglutide's ability to reduce alcohol intake in rats.Frontiers in pharmacology · 2023Article
- A novel human laboratory alcohol self-administration paradigm for medication screening: Modeling the ability to resist drinking and heavy drinking.Drug and alcohol dependence reports · 2022Article
- Mice lacking α4 nicotinic acetylcholine receptors are protected against alcohol-associated liver injury.Alcoholism, clinical and experimental research · 2022Article
- Limitations of cross-lagged panel models in addiction research and alternative models: An empirical example using project MATCH.Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors · 2022Article
- Pharmacotherapies and personalized medicine for alcohol use disorder: a review.Pharmacogenomics · 2020Review
- Prospects for pharmacotherapies to treat alcohol use disorder: an update on recent human studies.Current opinion in psychiatry · 2019Review
- Medications for alcohol use disorders: An overview.Pharmacology & therapeutics · 2018Review
- The Corticotropin Releasing Factor Receptor 1 in Alcohol Use Disorder: Still a Valid Drug Target?Alcoholism, clinical and experimental research · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Varenicline (VAR) is approved to aid in smoking cessation and has been shown to be effective for reducing alcohol consumption in heavy drinkers. Little is known, however, about treatment moderators that may influence efficacy. The current study reanalyzed data from a human laboratory study (Verplaetse et al., 2016) to determine whether VAR was more effective at reducing alcohol use among drinkers reporting symptoms of depression. Participants were 60 adults meeting DSM-IV criteria for alcohol use disorders ( n = 60) who were randomly assigned to receive VAR (1 mg/day, 2 mg/day) or placebo. Following 7 days of medication pretreatment, participants attended a laboratory testing session. They provided self-reported ratings of alcohol craving and performed an ad libitum alcohol consumption task after receiving a priming dose of alcohol (target blood alcohol concentration = 0.030 g/dL). Higher blood VAR plasma levels were associated with less alcohol craving and less drinking among participants with more depressive symptoms. Among participants with fewer depressive symptoms, VAR was associated with more drinking during the ad libitum drinking task. These findings show that depression symptoms may be a moderator of VAR efficacy in alcohol users and provides evidence for the role of nAChRs in depression and alcohol use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.